Kringle Pharma, Inc. AI Stock Analysis
Want to see JP:4884 full AI Analyst Report?
Kringle Pharma, Inc. (4884) AI Stock Analysis
Kringle Pharma, Inc.
(TSE/TYO:4884)
The overall score of 50.5 reflects a company with a stable, debt-free foundation but significant operational risks. The primary strength is the strong balance sheet, which provides a runway. The most significant weaknesses are the deep net losses and heavy cash burn, which are only partially offset by a recent surge in revenue. Moderately bullish technical trends provide some support, but the negative P/E ratio underscores the lack of current profitability.
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.79B
- Dividend Yield
- ―
- Average Volume (3M)
- 282.72K
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 0.59
- Revenue Growth
- 513.34%
- EPS Growth
- 20.92%
- Country
- Japan
- Employees
- 17
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious med...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Financial performance is mixed. A pristine, debt-free balance sheet (Score 72) provides stability, but this is offset by deep unprofitability (Income Score 35) and significant cash burn (Cash Flow Score 30). The recent revenue surge is a positive signal, yet the overall financial health is pressured by unsustainable losses and cash outflows.
Income Statement
35NegativeBalance Sheet
72PositiveCash Flow
30Negative| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.47M | 442.92M | 72.22M | 80.04M | 69.25M | 391.83M |
| Gross Profit | 234.20M | 372.54M | 72.22M | 0 | 0 | 303.42M |
| EBITDA | -806.45M | -813.45M | -909.45M | -817.88M | -888.76M | -426.17M |
| Net Income | -808.44M | -813.64M | -916.25M | -756.45M | -854.15M | -331.83M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 1.98B | 2.08B | 2.76B | 2.62B | 3.21B |
| Cash, Cash Equivalents and Short-Term Investments | 1.70B | 1.68B | 1.62B | 2.31B | 2.14B | 2.76B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 744.51M | 810.41M | 770.11M | 648.92M | 596.95M | 419.50M |
| Stockholders Equity | 1.25B | 1.17B | 1.31B | 2.11B | 2.02B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | 0 | -661.17M | -689.10M | 15.80M |
| Operating Cash Flow | -755.78M | -563.22M | -755.78M | -661.17M | -689.10M | 15.80M |
| Investing Cash Flow | -154.01M | -16.48M | -154.01M | -121.36M | -120.88M | -254.38M |
| Financing Cash Flow | 84.14M | 643.15M | 84.14M | 838.23M | 69.16M | 603.11M |
Kringle Pharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 557.00 is below the 20-day moving average (MA) of 563.30, above the 50-day MA of 525.26, and above the 200-day MA of 424.15, indicating a neutral trend. The MACD of -6.31 indicates Positive momentum. The RSI at 52.30 is Neutral, neither overbought nor oversold. The STOCH value of 59.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
Overall Rating
JP:488450.5Neutral
JP:458748Neutral
JP:459842Neutral
JP:457141Neutral
JP:459140Underperform
JP:488138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | JPY 4.79B | -5.26 | ― | ― | 513.34% | 20.92% | |
| 48Neutral | JPY 138.26B | -47.73 | -5.85% | ― | 14.25% | 50.07% | |
| 42Neutral | JPY 1.25B | -0.45 | ― | ― | ― | 20.94% | |
| 41Neutral | JPY 6.10B | -4.20 | -39.57% | ― | 48.92% | -46.91% | |
| 40Underperform | JPY 3.31B | -2.63 | ― | ― | ― | 9.55% | |
| 38Underperform | JPY 1.98B | -1.13 | ― | ― | -27.93% | 22.36% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4884 | Kringle Pharma, Inc. | 557.00 | 128.00 | 29.84% | |
| JP:4587 | Peptidream | 1065.00 | -518.50 | -32.74% | |
| JP:4571 | NanoCarrier Co., Ltd. | 67.00 | -83.00 | -55.33% | |
| JP:4591 | Ribomic, Inc. | 58.00 | -26.00 | -30.95% | |
| JP:4598 | Delta-Fly Pharma, Inc. | 62.00 | -486.00 | -88.69% | |
| JP:4881 | FunPep Company Limited | 39.00 | -50.00 | -56.18% |
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Wins FDA IND Clearance for Spinal Cord Injury Drug
Kringle Pharma has secured clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for oremepermin alfa, a recombinant human hepatocyte growth factor therapy for acute spinal cord injury. The decision allows...
Kringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drug
Kringle Pharma has submitted an Investigational New Drug application to the U.S. FDA seeking to initiate a Phase 3 clinical trial of oremepermin alfa, a recombinant human hepatocyte growth factor, for the treatment of acute spinal cord injury in the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
